



## Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12

POINT RICHMOND, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will host a webcast and teleconference with management to discuss third quarter 2009 financial results on Thursday, November 12, 2009, at 5:00 p.m. Eastern Standard Time. Financial results for the third quarter ended September 30, 2009 will be released earlier that afternoon.

### Conference Call Information

Date: Thursday, November 12, 2009  
Time: 5:00 p.m. EST  
Dial-in (U.S.): 877-874-1589  
Dial-in (International): 719-325-4805

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at [www.transcept.com](http://www.transcept.com). A replay of this webcast will be available on the website beginning shortly after the conclusion of the call through November 27, 2009.

A telephone replay of the conference call will be available beginning shortly after the conclusion of the call through November 27, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 2918743.

### *About Transcept*

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is *Intermezzo*(R) (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the *Intermezzo*(R) NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of *Intermezzo*(R) in the United States. For further information, please visit the company's website at: [www.transcept.com](http://www.transcept.com).

### Contacts:

Transcept Pharmaceuticals, Inc.  
Greg Mann  
Director of Corporate Communications  
(510) 215-3567  
[gmann@transcept.com](mailto:gmann@transcept.com)

SOURCE Transcept Pharmaceuticals, Inc.

<http://www.transcept.com>

Copyright (C) 2009 PR Newswire. All rights reserved